Learn before you link.

MN Pharmaceuticals was established in 1923 and developed a healthcare and pharmaceutical heritage spanning more than a century. In 2012, Amgen acquired MN Pharmaceuticals in a publicly announced transaction. Amgen subsequently renamed the company Gensenta in 2020.

The name rights relating to MN Pharmaceuticals were later transferred to the current MN ownership structure, and MN Nutra represents the fourth-generation continuation of the healthcare heritage that began more than a century ago.

MN Nutra is the fourth-generation continuation of the MN Pharmaceuticals healthcare heritage, combining more than a century of formulation experience with independently developed Micro Matrix Technology and modern finished-product research.

Important: MN Nutra is not owned by, affiliated with, or endorsed by Amgen or Gensenta. The products, technology, and research are independently developed by the current MN ownership structure.

Mehmet Nevzat Pisak, President of MN Nutra, has spent more than 20 years working on pharmaceutical and nutritional formulations designed to improve delivery efficiency, enhance product performance and reduce formulation-related side effects. His publicly searchable patent portfolio includes multiple invention families covering pharmaceutical combinations, gastroprotective approaches, oral delivery systems, curcuminoid formulations and bioavailability-focused compositions.

Key takeaway for affiliates: When discussing heritage, always use the approved language. Say 'fourth-generation continuation of MN Pharmaceuticals healthcare heritage' — never claim affiliation with Amgen or Gensenta. The heritage is about formulation expertise and scientific tradition, not corporate ownership.

Micro Matrix Technology is MN Nutra's proprietary formulation platform. It was independently developed by the current MN ownership structure and is not derived from any Amgen or Gensenta technology.

The core challenge: Many beneficial compounds (curcumin, CBD from hemp, beta-glucan) have poor water solubility and low oral bioavailability. This means the body absorbs only a fraction of what you swallow. Micro Matrix Technology addresses this through a multi-stage micronization and matrix-embedding process.

How it works — the seven principles: (1) Particle size reduction to increase surface area. (2) Amorphous solid dispersion to improve dissolution rate. (3) Matrix embedding for stability and controlled release. (4) Surfactant integration for wetting and solubilisation. (5) Gastric protection where needed. (6) Coordinated multi-ingredient release profiles. (7) Manufacturing scalability using GRAS excipients only.

What Micro Matrix delivers: Higher peak plasma concentration (Cmax), greater total exposure (AUC), faster time to peak (Tmax), and lower variability between individuals. COMPLIANCE NOTE: describe this as better absorption. Never describe it as reaching a therapeutic level, and never present absorption as proof of a health outcome.

Evidence: The CBDNext Supra Capsule human pharmacokinetic study (Journal of Cannabis Research, 2025) showed a higher peak plasma level and greater total exposure than a standard CBD isolate from hemp capsule, in 9 healthy adults on a single 40 mg dose under fed conditions. NovoCurmin, the micronized curcumin platform in ImmuCurc, GeLiPthin-1 and Cortexa, shows 89 mg/mL water solubility against roughly 1–2 mg/mL for standard curcumin extract. COMPLIANCE NOTE: both are absorption measurements. Neither is evidence of a health outcome, and the study design must travel with any figure you quote.

Key takeaway for affiliates: Micro Matrix is the technology spine that connects all MN Nutra products. It's what makes MN Nutra a platform company, not just a supplement brand. When explaining to customers, focus on 'better absorption means your body can actually use what you're taking' — but never claim it cures or treats any disease.

Stage 1 — Raw Material Selection: Only GRAS (Generally Recognized As Safe) excipients accepted by major regulatory authorities worldwide. Each ingredient is sourced with certificates of analysis, identity testing, and heavy metal screening.

Stage 2 — Micronization: Active compounds are reduced to controlled particle sizes (target: ≥80% of particles ≤10 µm for beta-glucan; similar specifications for curcumin and CBD from hemp). This dramatically increases surface area for dissolution.

Stage 3 — Matrix Formation: Micronized actives are embedded within a proprietary solid matrix using specific surfactant-to-active ratios. This creates a stable micro-network that protects the active during storage and transit through the stomach.

Stage 4 — Amorphous Conversion: Where applicable, crystalline compounds are converted to amorphous form during matrix embedding. Amorphous forms dissolve faster than crystalline equivalents because they lack the energy barrier of crystal lattice disruption.

Stage 5 — Stability Optimisation: Each batch undergoes accelerated stability testing. The matrix must maintain particle size distribution, dissolution profile, and assay values through the product's shelf life (typically 24–36 months).

Stage 6 — Finished Dosage Form: The stabilised matrix is filled into capsules, compressed into tablets, or formulated as powder sachets depending on the product line. Each format is tested for dissolution, disintegration, and content uniformity.

Stage 7 — Quality Release: Final products are tested against specification for identity, assay, dissolution, microbiology, heavy metals, and stability. Only batches meeting all specifications are released for distribution.

Patent protection: MN Nutra's patent portfolio includes 65+ filings across PCT, US, European, and national jurisdictions (2019–2026). These cover the specific formulation compositions, not the general concept of micronization.

Key takeaway for affiliates: You don't need to explain all seven stages to customers. The simple message is: 'MN Nutra uses a patented manufacturing process that makes ingredients more absorbable, so your body gets more benefit from each dose.' Always reference that this is backed by a published human study.

Evidence hierarchy — what counts most: (1) Finished-product human studies in a healthy population, measuring an ordinary outcome. (2) Ingredient-level human studies, same conditions. (3) Preclinical and bioavailability characterisation. (4) Mechanistic data — explains why something should work.

LEVEL 1 — CBDNext Supra Capsule has a published finished-product human study (Journal of Cannabis Research, 2025): randomized three-way crossover, 9 healthy adults, single 40 mg dose, fed conditions. Two limits travel with it. It measured ABSORPTION, not a health outcome. And CBDNext is not one of the products you promote to consumers — none of the four supplements has a finished-product human study, so say that plainly if a customer asks.

LEVEL 2 — this is where the real substantiation sits, and it is where you should reach first. Saffron: a randomized placebo-controlled trial in healthy adults showing reduced snacking events over 8 weeks. Curcumin: improved working memory and attention in healthy older adults. PQQ: improved cognitive function scores in middle-aged and elderly subjects. Nicotinamide riboside: increased blood NAD+ levels in healthy subjects. Trans-resveratrol: increased cerebral blood flow in healthy adults. Green tea catechins and capsaicinoids: increased energy expenditure in healthy subjects. Every one of these was run in people who were not patients, and measured an ordinary outcome.

LEVEL 3 — NovoCurmin: 89 mg/mL water solubility and improved Cmax versus standard curcumin, from preclinical characterisation. This substantiates the delivery technology. It does not substantiate a health outcome.

LEVEL 4 — mechanism. Dectin-1 receptor recognition of micronized beta-glucan in gut-associated lymphoid tissue. Saccharomyces boulardii as a non-colonising probiotic yeast supporting gut flora balance. Curcumin and NF-kB signalling. Mechanism explains the formulation rationale; it is not evidence of an effect.

WHAT MAY NEVER BE CITED: any study conducted in a patient population, or measuring a disease outcome. The micronized beta-glucan dossier is the case to know — every endpoint in it is a disease outcome, so none of it may be used, in any framing, including as an ingredient study or as a link. The same applies to the GeLiPthin-1 preclinical study and to any berberine, NMN or resveratrol trial run in a clinical population.

Key takeaway for affiliates: be honest about the evidence level, and reach for the Level 2 studies. They are in healthy people, they measure ordinary outcomes, and they support exactly the claims you are allowed to make. If you feel you need a disease study to close a sale, you are about to make a claim you may not make. Never say 'clinically proven' for any product in the range.

The FTC Act requires that advertising claims be truthful, not misleading, and substantiated. As an MN Nutra affiliate, you are legally responsible for the claims you make about our products.

APPROVED language (structure/function claims): 'Helps support healthy immune function' · 'Designed to support cognitive performance' · 'Formulated to help maintain healthy weight management' · 'May help support joint comfort' · 'Contains ingredients that support cellular energy production'. Always pair with the FDA disclaimer.

PROHIBITED language (disease claims — NEVER use): 'Cures cancer' · 'Treats diabetes' · 'Prevents Alzheimer's' · 'Reduces tumour size' · 'Lowers blood pressure' · 'Heals inflammation' · 'Anti-viral' · 'Fights COVID'. Any claim that a supplement diagnoses, treats, cures, or prevents a disease is illegal under DSHEA.

Required FDA disclaimer (must appear with any structure/function claim): '*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.'

Testimonial rules: Never fabricate customer reviews or testimonials. If sharing your own experience it must be truthful — and note that 'Individual results may vary' does NOT make a specific result safe to publish. See module 8; MN Nutra does not permit specific personal result figures at all.

Income claims: Never publish earnings figures or income projections for the affiliate program at all. MN Nutra does not publish average-earnings data, and without it an earnings claim cannot be substantiated — a disclaimer does not cure that.

Social media requirements: All paid partnerships and affiliate relationships must be clearly disclosed using #ad, #sponsored, or 'Paid partnership with MN Nutra' — placed where viewers will see it before engaging with the content (not buried in hashtags).

Escalation protocol: If a customer asks whether a product can help with a specific medical condition, respond: 'I'm not qualified to give medical advice. Please consult your healthcare provider. I can share information about the ingredients and the published research if that's helpful.' Never diagnose or prescribe.

Key takeaway: When in doubt, ask yourself: 'Am I claiming this product treats or prevents a disease?' If yes, don't say it. Stick to structure/function language ('helps support'), always include the FDA disclaimer, and always disclose your affiliate relationship.

Federal law requires MN Nutra to report a SERIOUS adverse event to the FDA within 15 business days of RECEIVING the report. The clock starts when the report reaches anyone acting for MN Nutra — and that includes you. If a report reaches you and stops there, the deadline is running and nobody at MN Nutra knows.

What counts as serious: death; a life-threatening experience; inpatient hospitalisation; a persistent or significant disability or incapacity; a congenital anomaly or birth defect; an event requiring medical or surgical intervention to prevent one of the outcomes above.

You are not asked to apply that list. It is here so you recognise the shape of the thing, not so you can triage it — triage is exactly where reports get lost.

THREE RULES, AND ONLY THREE. (1) Do not give medical advice. Tell the person to seek medical attention if they need it. (2) Do not decide whether it is serious, or whether the product caused it. That judgement is not yours to make and making it is how reports get lost. (3) Escalate immediately, every time — even if you think the person is mistaken, exaggerating or hostile.

Where to send it: safety@mnnutra.com. Same day. Forward the message itself — a screenshot of the comment or DM, the person's own words, and the date you received it. Do not summarise it and do not clean it up; the original wording is the record.

The realistic case is ordinary, not dramatic. Someone comments under your post that they took a product and ended up in hospital. Or a follower sends a DM describing a reaction that needed emergency treatment. It will not arrive labelled as a regulatory matter. It will arrive as a message from a stranger who is upset.

What not to do: do not reply with medical advice, do not promise anything about the product, do not argue, and do not delete the message. Say you are sorry to hear it, suggest they seek medical attention, tell them you are passing it to MN Nutra, and then actually pass it on.

IT USUALLY ARRIVES PRIVATELY. A comment under your post is visible — MN Nutra samples public content and may see it. A direct message, a personal email or a phone call is not. Nobody at MN Nutra can see those, ever. That is exactly why this duty sits with you rather than with a system, and it is why a report that reaches you privately is the one most likely to be lost.

YOU WILL NEVER BE PENALISED FOR FORWARDING. Forwarding a report is never held against you — not if it turns out to be unrelated, not if the person was mistaken, and not if it concerns your own post. Failing to forward one is a breach of this agreement. There is no version of this where passing it on costs you anything.

Say that again, because it is the part people do not believe: forwarding a report about YOUR OWN post, YOUR OWN claim or YOUR OWN mistake is still never held against you. The mistake is a separate conversation, and it is a small one. Sitting on a report is not.

You will be asked to confirm this every time you request a payout. Certification happens once a year; that prompt happens whenever you want to be paid, which is the point.

Key takeaway for affiliates: you are not being asked to judge whether a report is credible or product-related. You are being asked to move it, unfiltered, within the same day. Forwarding something that turns out to be nothing costs nobody anything. Not forwarding something that turns out to be serious is the one mistake in this programme that cannot be corrected afterwards.

Everything you have learned so far is about language: which phrases are permitted, which are forbidden, how to tell 'studied' from 'shown' from 'proven'. That training carries an implication which is not true — that compliance is a property of words.

The actual test is the NET IMPRESSION of the whole communication. The FTC directs marketers to assess each advertisement as a whole, including the text, the product name, and any charts, graphs and images. You are equally responsible for what is implied, the standard is what a reasonable consumer understands rather than what you intended, and if a post supports more than one reasonable reading, each of them has to be true.

The FDA gets to the same place by another route. 21 CFR 101.93(g)(2) says a disease claim can be implied through the product's name, its formulation, a citation whose reference is to a disease use, or — in the regulation's own words — 'pictures, vignettes, symbols or other means'. A rule written a quarter of a century ago anticipated the image-led social post exactly.

IMAGERY THAT MAKES CLAIMS. White coats, stethoscopes, microscopes, laboratory glassware and stacks of journals imply the product is clinically proven. Pictures of symptoms — a person clutching a joint, someone sneezing — imply treatment of the thing depicted. A chart placed beside a product implies the product caused the effect shown. None of that needs a caption to be a claim.

THE TRAP FOR A CAREFUL AFFILIATE. You already know a citation can be a claim. So you post the GRAPH from a study instead of quoting its conclusion — and you have not become safer, because the graph carries the implication on its own. It is entirely possible to assemble a disease claim from a stock photo, a product shot and no words at all, while every word you used would pass the exam.

A post with no words is still an endorsement. Tags, likes, pins and simply posting a picture of a product can convey approval, so an image-only post is simultaneously an endorsement that needs disclosure and a claim that needs substantiation.

WORKED PAIR — identical caption, different outcome. Caption in both: 'My daily NovoCurmin. #ad'. COMPLIANT: the product on a kitchen counter. NON-COMPLIANT: the product beside a stethoscope and a printed study. Same words, and the second one claims clinical proof.

WORKED PAIR — no caption at all. COMPLIANT: product photo, disclosure on screen. NON-COMPLIANT: product photo next to a stock image of someone in bed with a thermometer. The second is a cold-treatment claim made entirely in pictures.

USE MN NUTRA'S IMAGERY. Approved assets exist so you never need stock photography. Do not use clinical or laboratory settings, medical professionals, depictions of symptoms or conditions, or charts from studies.

Key takeaway for affiliates: stop asking 'did I say anything forbidden?' and start asking 'what would someone take away from this post as a whole?' That is the question the regulators actually ask.

This module exists because the fix every affiliate reaches for is the one that does not work.

The FTC's position: an endorsement claiming specific results will usually be read as meaning the endorser's experience is what others can expect too — and statements such as 'results not typical' or 'individual results may vary' WILL NOT CHANGE that interpretation. Not that they are weaker than ideal. That they do not change it.

So if you write 'I lost twenty pounds in two months', you are legally read as claiming that a customer will lose about twenty pounds in two months. Your honest personal experience has become a general efficacy claim about the product, and MN Nutra has to be able to substantiate it.

There are only two lawful ways to publish a specific result: hold adequate proof that the result is TYPICAL across users, or state the generally expected outcome clearly and conspicuously beside the exceptional one. Both need outcome data across the customer base, and MN Nutra does not hold that data.

MN NUTRA'S RULE, therefore: do not publish specific personal result figures. No numbers, no timeframes, no before-and-after images. You may say a product is part of your routine and how you find it. You may not quantify what it did for you.

The related trap: where a study's subjects also dieted and exercised, any reference to the resulting effect has to make clear that users would need to do the same. The conditions travel with the claim — and the conditions are exactly the part people leave out, because they are the uninteresting part.

Key takeaway for affiliates: this is the single most likely mistake a careful, fully certified affiliate makes. They pass the exam, avoid every prohibited phrase, never mention a disease — and post 'down fourteen pounds in six weeks, results may vary', because everything else in their training suggested the disclaimer covered it. It does not.

Disclosure is not one rule. What counts as clear and conspicuous depends on the format, and the rules below are the specification — not guidance to interpret.

The governing standard: a disclosure must be difficult to miss and easily understood; where a representation is made through both visual and audible means it must appear in both (16 CFR 255.0(f)); and in an interactive medium it must be UNAVOIDABLE — it is not clear and conspicuous if the consumer has to take any action, such as tapping 'more' or opening a comment, to see it (16 CFR 465.1(c)(4)).

FEED POST (IMAGE OR CAROUSEL) — Required: Disclosure in the first line of the caption, before any “more” cut-off, in the same language as the post. Not enough: Buried among hashtags; In a comment, pinned or not; In your bio only.

STORY AND OTHER DISAPPEARING PICTURE CONTENT — Required: Superimposed on the image itself, on screen long enough to be noticed and read at normal viewing speed. MN Nutra approval required BEFORE publishing — see Agreement §6.1. Not enough: A link sticker; A caption that is only visible if the viewer taps.

SHORT-FORM VIDEO (REELS, TIKTOK, SHORTS) — Required: On-screen text near the start AND spoken in the audio. Both, because the representation is made through both means. Not enough: Caption text only; The video description; A pinned comment; The platform's own “paid partnership” label on its own.

LONG-FORM VIDEO — Required: Spoken disclosure within the first 30 seconds AND on-screen text, repeated if the video is long enough that viewers join partway. Not enough: Description only; End-card only.

LIVE STREAM — Required: Stated PERIODICALLY throughout the stream, so that a viewer joining halfway through still receives it. MN Nutra approval required BEFORE going live — see Agreement §6.1. Not enough: Once at the start; In the stream title only; In the chat.

BLOG OR LONG-FORM WRITTEN — Required: Adjacent to the link, close enough that a reader can see the disclosure and the link at the same time. A single disclosure at the top is enough only if that stays true. Not enough: One disclosure at the top of a long article with links far below; A site-wide disclosure page.

EMAIL — Required: In the body, above or beside the link, not in the footer. Commercial email also carries CAN-SPAM duties — see Agreement §5.9. Not enough: Footer boilerplate; The unsubscribe block.

WORDINGS THAT WORK: Ad · Advertisement · Sponsored · Paid link · Paid partnership with MN Nutra · I get commissions for purchases made through links in this post.

WORDINGS THAT DO NOT: Affiliate link · Commissionable link · A “buy now” button on its own · sp · spon · collab · Thanks @MNNutra · Ambassador · A disclosure in your bio only · The platform's own tool on its own. "Affiliate link" heads that list because it is the most common choice and the one affiliates are most surprised to find inadequate — a consumer may not understand it to mean you are paid.

ALWAYS, WHATEVER THE FORMAT: Every post needs its own disclosure. Viewers may not have seen your previous ones. An ongoing relationship with MN Nutra is disclosed even when you bought the product yourself. Disclosure is required on an unpaid bonus post, and on any other platform you cross-post to. Disclosure is required even when you are criticising a competitor of the brand that pays you.

Key takeaway for affiliates: if you find yourself deciding whether something counts, you have already left the specification. Use an approved wording, put it where it cannot be missed without tapping anything, and put it on every post.